TY - JOUR
T1 - HAI chemotherapy for liver metastases of colorectal cancer
AU - Matsuoka, Hiroshi
AU - Maeda, Kotaro
AU - Hanai, Tsunekazu
AU - Sato, Harunobu
AU - Masumori, Kouji
AU - Koide, Yoshikazu
AU - Katsuno, Hidetoshi
AU - Agata, Toshihisa
AU - Noro, Tomohito
AU - Honda, Katsuyuki
AU - Shiota, Miho
AU - Ozeki, Shinji
AU - Hatta, Kouhei
AU - Morise, Zenichi
AU - Sugioka, Atsushi
AU - Ota, Hideki
PY - 2010/7/15
Y1 - 2010/7/15
N2 - We evaluated the effect of hepatic arterial infusion (HAI) chemotherapy for liver metastases from colorectal cancer. A total of 65 patients received HAI chemotherapy. The chemotherapy regimen consisted of weekly 5-FU (1, 500 mg/body) or 5-FU (400 mg/mm2) and /-LV (200 mg/mm2). The survival and response rates were assessed according to RECIST. Median survival time with HAI chemotherapy was 13.5 months, 5-year survival rate 8% and response rates 55%. There was no evidence of myelosuppression, and HAI could be continued for a long time even for poor PS patients. There were no differences in survival time between synchronous, metachronous and postoperative metachronous liver metastases. In the patients who underwent curative hepatectomy after HAI chemotherapy, the 5-year survival rate was 21%, which was better than in patients with HAI chemotherapy alone. HAI chemotherapy could thus be an option for unresectable liver metastases, which could be well tolerated.
AB - We evaluated the effect of hepatic arterial infusion (HAI) chemotherapy for liver metastases from colorectal cancer. A total of 65 patients received HAI chemotherapy. The chemotherapy regimen consisted of weekly 5-FU (1, 500 mg/body) or 5-FU (400 mg/mm2) and /-LV (200 mg/mm2). The survival and response rates were assessed according to RECIST. Median survival time with HAI chemotherapy was 13.5 months, 5-year survival rate 8% and response rates 55%. There was no evidence of myelosuppression, and HAI could be continued for a long time even for poor PS patients. There were no differences in survival time between synchronous, metachronous and postoperative metachronous liver metastases. In the patients who underwent curative hepatectomy after HAI chemotherapy, the 5-year survival rate was 21%, which was better than in patients with HAI chemotherapy alone. HAI chemotherapy could thus be an option for unresectable liver metastases, which could be well tolerated.
UR - http://www.scopus.com/inward/record.url?scp=79961105060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79961105060&partnerID=8YFLogxK
M3 - Article
C2 - 20647714
AN - SCOPUS:79961105060
SN - 0385-0684
VL - 37
SP - 1303
EP - 1306
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 7
ER -
